HomepageBSLN • SWX
add
Basilea Pharmaceutica
Vorige slotkoers
CHFÂ 44,85
Dag-range
CHFÂ 44,05 - CHFÂ 45,50
Jaar-range
CHFÂ 36,75 - CHFÂ 48,75
Beurswaarde
580,23Â mln. CHF
Gem. volume
42,09K
Koers/winst
7,87
Dividendrendement
-
Primaire beurs
SWX
Marktnieuws
Financiële informatie
Resultatenrekening
Opbrengst
Netto inkomsten
| (CHF) | dec 2024info | Wijziging j-o-j |
|---|---|---|
Opbrengst | 66,12Â mln. | 81,84% |
Bedrijfskosten | 7,98Â mln. | 0,24% |
Netto inkomsten | 28,43Â mln. | 365,82% |
Netto winstmarge | 42,99 | 246,17% |
Winst per aandeel | — | — |
EBITDA | 26,89Â mln. | 464,63% |
Effectief belastingtarief | -7,41% | — |
Balans
Totale activa
Totale passiva
| (CHF) | dec 2024info | Wijziging j-o-j |
|---|---|---|
Contanten en kortetermijnbeleggingen | 120,71Â mln. | 101,41% |
Totale activa | 257,76Â mln. | 48,75% |
Totale passiva | 176,76Â mln. | -3,56% |
Totaal aandelenvermogen | 81,00 mln. | — |
Uitstaande aandelen | 12,13 mln. | — |
Koers-boekwaardeverhouding | 6,71 | — |
Rendement op activa | 25,30% | — |
Rendement op kapitaal | 33,85% | — |
Kasstroom
Nettomutatie in liquide middelen
| (CHF) | dec 2024info | Wijziging j-o-j |
|---|---|---|
Netto inkomsten | 28,43Â mln. | 365,82% |
Operationele kasstroom | 28,22Â mln. | 840,82% |
Kasstroom uit beleggingen | -636,00K | -97,21% |
Kasstroom uit financiering | -11,00K | 99,95% |
Nettomutatie in liquide middelen | 27,54Â mln. | 213,29% |
Vrije kasstroom | 17,85Â mln. | 533,14% |
Over
Basilea Pharmaceutica is a biopharmaceutical company based in Allschwil near Basel, Switzerland. Basilea was spun off from F. Hoffmann-La Roche in 2000 and has been listed as an independent company on the Swiss stock exchange since March 2004. The company's subsidiary is Basilea Pharmaceutica International AG, Allschwil, which is also based in Allschwil, Switzerland, and in which the company's operating activities are bundled. Wikipedia
CEO
Opgericht
2000
Website
Werknemers
164
